0	4	Role	role	NN
5	7	of	of	IN
8	13	Egr-2	egr-2	NN
14	16	in	in	IN
17	30	up-regulation	up-regulation	NN
31	33	of	of	IN
34	37	Fas	Fas	NNP
38	44	ligand	ligand	NN
45	47	in	in	IN
48	54	normal	normal	JJ
55	56	T	t	NN
57	62	cells	cell	NNS
63	66	and	and	CC
67	75	aberrant	aberrant	JJ
76	91	double-negative	double-negative	JJ
92	95	lpr	lpr	NN
96	99	and	and	CC
100	103	gld	gld	NN
104	105	T	t	NN
106	111	cells	cell	NNS
111	112	.	.	.

114	116	We	we	PRP
117	127	previously	previously	RB
128	138	identified	identify	VBD
139	140	a	a	DT
141	144	Fas	Fas	NNP
145	151	ligand	ligand	NN
152	162	regulatory	regulatory	JJ
163	170	element	element	NN
171	172	(	(	(
172	176	FLRE	FLRE	NNP
176	177	)	)	)
178	180	in	in	IN
181	184	the	the	DT
185	188	Fas	Fas	NNP
189	195	ligand	ligand	NN
196	197	(	(	(
197	201	fasL	fasl	NN
201	202	)	)	)
203	211	promoter	promoter	NN
212	216	that	that	WDT
217	222	binds	bind	VBZ
223	226	Egr	Egr	NNP
227	233	family	family	NN
234	242	proteins	protein	NNS
243	246	and	and	CC
247	259	demonstrated	demonstrate	VBD
260	264	that	that	IN
265	270	Egr-3	Egr-3	NNP
271	272	(	(	(
272	277	PILOT	PILOT	NNP
277	278	)	)	)
279	282	but	but	CC
283	286	not	not	RB
287	292	Egr-1	egr-1	NN
293	294	(	(	(
294	300	NGFI-A	NGFI-A	NNP
300	301	,	,	,
302	309	Krox-24	Krox-24	NNP
309	310	,	,	,
311	316	Tis-8	tis-8	NN
316	317	,	,	,
318	321	and	and	CC
322	329	Zif-268	zif-268	NN
329	330	)	)	)
331	338	induces	induce	VBZ
339	352	transcription	transcription	NN
353	355	of	of	IN
356	360	fasL	fasl	NN
360	361	.	.	.

362	365	The	the	DT
366	374	aberrant	aberrant	JJ
375	387	CD4(-)CD8(-)	cd4(-)cd8(-)	JJ
388	389	T	t	NN
390	395	cells	cell	NNS
396	400	from	from	IN
401	408	lpr/lpr	lpr/lpr	NN
409	412	and	and	CC
413	420	gld/gld	gld/gld	NN
421	425	mice	mouse	NNS
425	426	,	,	,
427	432	which	which	WDT
433	437	have	have	VBP
438	447	mutations	mutation	NNS
448	450	in	in	IN
451	454	the	the	DT
455	460	genes	gene	NNS
461	469	encoding	encode	VBG
470	473	Fas	Fas	NNP
474	477	and	and	CC
478	482	FasL	FasL	NNP
482	483	,	,	,
484	496	respectively	respectively	RB
496	497	,	,	,
498	502	have	have	VBP
503	505	an	an	DT
506	515	activated	activate	VBN
516	525	phenotype	phenotype	NN
526	529	and	and	CC
530	544	constitutively	constitutively	RB
545	552	express	express	VBP
553	557	high	high	JJ
558	564	levels	level	NNS
565	567	of	of	IN
568	572	fasL	fasl	NN
573	577	mRNA	mrna	NN
577	578	,	,	,
579	588	prompting	prompt	VBG
589	591	us	us	PRP
592	594	to	to	TO
595	598	ask	ask	VB
599	603	what	what	WP
604	608	role	role	NN
609	611	if	if	IN
612	615	any	any	DT
616	619	the	the	DT
620	624	FLRE	FLRE	NNP
625	628	and	and	CC
629	632	Egr	Egr	NNP
633	639	family	family	NN
640	648	proteins	protein	NNS
649	653	have	have	VBP
654	656	in	in	IN
657	661	this	this	DT
662	670	aberrant	aberrant	JJ
671	681	expression	expression	NN
682	684	of	of	IN
685	689	fasL	fasl	NN
689	690	.	.	.

691	703	Unstimulated	unstimulated	JJ
704	715	MRL-lpr/lpr	MRL-lpr/lpr	NNP
716	719	and	and	CC
720	731	C3H-gld/gld	c3h-gld/gld	JJ
732	744	CD4(-)CD8(-)	cd4(-)cd8(-)	JJ
745	746	T	t	NN
747	752	cells	cell	NNS
753	767	constitutively	constitutively	RB
768	777	contained	contain	VBD
778	782	high	high	JJ
783	789	levels	level	NNS
790	792	of	of	IN
793	796	two	two	CD
797	805	proteins	protein	NNS
806	810	that	that	WDT
811	816	bound	bind	VBD
817	819	to	to	TO
820	823	the	the	DT
824	828	FLRE	flre	NN
828	829	.	.	.

830	840	Supershift	Supershift	NNP
841	849	analysis	analysis	NN
850	858	revealed	reveal	VBD
859	864	these	these	DT
865	873	proteins	protein	NNS
874	876	to	to	TO
877	879	be	be	VB
880	885	Egr-1	egr-1	NN
886	889	and	and	CC
890	895	Egr-2	egr-2	NN
896	897	(	(	(
897	904	Krox-20	Krox-20	NNP
904	905	)	)	)
905	906	;	;	:
907	912	Egr-3	Egr-3	NNP
913	916	was	be	VBD
917	920	not	not	RB
921	929	detected	detect	VBN
929	930	.	.	.

931	941	Activation	Activation	NNP
942	944	of	of	IN
945	951	normal	normal	JJ
952	957	lymph	lymph	NN
958	962	node	node	NN
963	968	cells	cell	NNS
969	977	resulted	result	VBD
978	980	in	in	IN
981	990	increased	increase	VBN
991	1001	expression	expression	NN
1002	1004	of	of	IN
1005	1010	Egr-1	Egr-1	NNP
1010	1011	,	,	,
1012	1014	-2	-2	CD
1014	1015	,	,	,
1016	1019	and	and	CC
1020	1022	-3	-3	CD
1022	1023	.	.	.

1024	1026	As	as	IN
1027	1031	with	with	IN
1032	1037	egr-3	egr-3	NN
1037	1038	,	,	,
1039	1049	expression	expression	NN
1050	1052	of	of	IN
1053	1058	egr-2	egr-2	NN
1059	1062	was	be	VBD
1063	1070	blocked	block	VBN
1071	1073	by	by	IN
1074	1085	cyclosporin	cyclosporin	NN
1086	1087	A	a	NN
1087	1088	.	.	.

1089	1097	Although	although	IN
1098	1111	overexpressed	overexpresse	VBN
1112	1117	Egr-1	egr-1	NN
1118	1121	was	be	VBD
1122	1133	ineffective	ineffective	JJ
1133	1134	,	,	,
1135	1148	overexpressed	overexpresse	VBN
1149	1154	Egr-2	egr-2	NN
1155	1158	was	be	VBD
1159	1161	as	as	RB
1162	1168	potent	potent	JJ
1169	1171	as	as	IN
1172	1177	Egr-3	egr-3	NN
1178	1180	in	in	IN
1181	1189	inducing	induce	VBG
1190	1194	fasL	fasl	NN
1195	1213	promoter-dependent	promoter-dependent	JJ
1214	1222	reporter	reporter	NN
1223	1233	constructs	construct	NNS
1234	1236	in	in	IN
1237	1238	T	t	NN
1239	1243	cell	cell	NN
1244	1254	hybridomas	hybridoma	NNS
1255	1258	and	and	CC
1259	1263	HeLa	HeLa	NNP
1264	1269	cells	cell	NNS
1269	1270	,	,	,
1271	1274	and	and	CC
1275	1279	both	both	DT
1280	1292	up-regulated	up-regulate	VBN
1293	1303	endogenous	endogenous	JJ
1304	1308	fasL	fasl	NN
1309	1313	mRNA	mrna	NN
1314	1316	in	in	IN
1317	1321	HeLa	HeLa	NNP
1322	1327	cells	cell	NNS
1327	1328	.	.	.

1329	1343	FasL-dependent	fasl-dependent	JJ
1344	1352	reporter	reporter	NN
1353	1363	constructs	construct	NNS
1364	1366	in	in	IN
1367	1378	MRL-lpr/lpr	MRL-lpr/lpr	NNP
1379	1382	and	and	CC
1383	1394	C3H-gld/gld	c3h-gld/gld	JJ
1395	1407	CD4(-)CD8(-)	cd4(-)cd8(-)	JJ
1408	1409	T	t	NN
1410	1415	cells	cell	NNS
1416	1420	were	be	VBD
1421	1435	constitutively	constitutively	RB
1436	1442	active	active	JJ
1442	1443	,	,	,
1444	1447	and	and	CC
1448	1452	this	this	DT
1453	1461	activity	activity	NN
1462	1465	was	be	VBD
1466	1473	largely	largely	RB
1474	1483	prevented	prevent	VBN
1484	1486	by	by	IN
1487	1495	mutation	mutation	NN
1496	1498	of	of	IN
1499	1502	the	the	DT
1503	1511	critical	critical	JJ
1512	1515	Egr	Egr	NNP
1516	1522	family	family	NN
1523	1530	binding	binding	NN
1531	1538	element	element	NN
1538	1539	.	.	.

1540	1544	Thus	thus	RB
1544	1545	,	,	,
1546	1551	Egr-2	Egr-2	NNP
1551	1552	,	,	,
1553	1555	in	in	IN
1556	1564	addition	addition	NN
1565	1567	to	to	TO
1568	1573	Egr-3	Egr-3	NNP
1573	1574	,	,	,
1575	1584	regulates	regulate	VBZ
1585	1589	FasL	FasL	NNP
1590	1600	expression	expression	NN
1601	1603	in	in	IN
1604	1613	activated	activate	VBN
1614	1620	normal	normal	JJ
1621	1622	T	t	NN
1623	1628	cells	cell	NNS
1628	1629	,	,	,
1630	1633	and	and	CC
1634	1639	Egr-2	egr-2	NN
1640	1642	is	be	VBZ
1643	1649	likely	likely	JJ
1650	1652	to	to	TO
1653	1657	play	play	VB
1658	1659	a	a	DT
1660	1666	direct	direct	JJ
1667	1671	role	role	NN
1672	1674	in	in	IN
1675	1683	aberrant	aberrant	JJ
1684	1688	fasL	fasl	NN
1689	1702	up-regulation	up-regulation	NN
1703	1705	in	in	IN
1706	1713	lpr/lpr	lpr/lpr	NN
1714	1717	and	and	CC
1718	1725	gld/gld	gld/gld	NN
1726	1738	CD4(-)CD8(-)	cd4(-)cd8(-)	JJ
1739	1740	T	t	NN
1741	1746	cells	cell	NNS
1746	1747	.	.	.